Mark D. Starr

2.8k citations

49 papers · 1.9k indexed · h-index 21

Impact in

Immunology top 5%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immune cells in cancer
Cell Biology top 5%
- Zebrafish Biomedical Research Applications

Papers in ⓘ

Oncology 23
- Colorectal Cancer Treatments and Studies 8
- Cancer Cells and Metastasis 4
Equine 1

Co-authors: Andrew B. Nixon (35 shared papers)Mervin C. Yöder (3 shared papers)Susan Mineka (1 shared paper)S.A. Johnson (2 shared papers)Xiaodong Xie (2 shared papers)Michael J. Ferkowicz (1 shared paper)Weiming Li (1 shared paper)W. Christopher Shelley (1 shared paper)
Journals: Journal of Clinical Oncology (8 papers)Cancer Medicine (4 papers)Journal of Clinical Investigation (3 papers)Molecular Cancer Therapeutics (3 papers)Developmental Psychology (2 papers)
Partner nations: United States Hong Kong Canada

In The Last Decade

Mark D. Starr

48 papers receiving 1.9k citations

Peers

Countries citing papers authored by Mark D. Starr

Since Specialization

Citations

This map shows the geographic impact of Mark D. Starr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Starr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Starr more than expected).

Fields of papers citing papers by Mark D. Starr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Starr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Starr. The network helps show where Mark D. Starr may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark D. Starr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark D. Starr Line = papers co-authored together Mark D. Starr links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor Current Biology ·K-D. Fischer, Young‐Yun Kong, Hiroshi Nishina, Kerry Tedford, Luc E. M. Marengère, I. Kozieradzki, Takehiko Sasaki, Mark D. Starr, Gordon Chan, S. Gardener, Mai P. Nghiem, Dennis Bouchard, Mariano Barbacid, Alan Bernstein, Josef Penninger	1998	380
2	CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo Development ·Michael J. Ferkowicz, Mark D. Starr, Xiaodong Xie, Weiming Li, S.A. Johnson, W. Christopher Shelley, Paul R. Morrison, Mervin C. Yöder	2003	260
3	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy Journal of Clinical Investigation ·Balamayoora Theivanthiran, Kathy S. Evans, Nicholas C. DeVito, Michael P. Plebanek, Michael Sturdivant, Lucas P. Wachsmuth, April K.S. Salama, Yubin Kang, David S. Hsu, Justin M. Balko, Douglas B. Johnson, Mark D. Starr, Andrew B. Nixon, Alisha Holtzhausen, Brent A. Hanks	2020	187
4	Spatial and temporal emergence of high proliferative potential hematopoietic precursors during murine embryogenesis Proceedings of the National Academy of Sciences ·James Palis, Rebecca J. Chan, Anne D. Koniski, Rahima Patel, Mark D. Starr, Mervin C. Yöder	2001	135
5	Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment Journal of Clinical Investigation ·Brent A. Hanks, Alisha Holtzhausen, Katherine S. Evans, Rebekah Jamieson, Petra Gimpel, Olivia Campbell, Melissa Hector-Greene, Lihong Sun, Alok K. Tewari, Amanda M. George, Mark D. Starr, Andrew B. Nixon, C. Augustine, Georgia M. Beasley, Douglas S. Tyler, Takayu Osada, Michael A. Morse, Leona Ling, H. Kim Lyerly, Gerard C. Blobe	2013	97
6	Determinants of fear over the course of avoidance learning Learning and Motivation ·Mark D. Starr, Susan Mineka	1977	93
7	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) Clinical Cancer Research ·Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz	2013	82
8	TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3 Carcinogenesis ·Rachel Hesler, Jennifer J. Huang, Mark D. Starr, Victoria Treboschi, Alyssa Bernanke, Andrew B. Nixon, Shannon J. McCall, Rebekah R. White, Gerard C. Blobe	2016	78
9	Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Cancer Medicine ·Yingmiao Liu, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, Andrew B. Nixon	2013	57
10	Chagas' Disease: Risk Factors for House Infestation by Triatoma dimidiata, the Major Vector of Trypanosoma cruzi in Costa Rica American Journal of Epidemiology ·Mark D. Starr, Julio C. Rojas, Rodrigo Zeledón, David W. Hird, Tim E. Carpenter	1991	43
11	Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion Molecular Biology of the Cell ·Jennifer Elderbroom, Jennifer J. Huang, Catherine E. Gatza, Jian Chen, Tam How, Mark D. Starr, Andrew B. Nixon, Gerard C. Blobe	2014	38
12	Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells Gynecologic Oncology ·Deanna Teoh, Tina A. Ayeni, Jennifer M. Rubatt, David J. Adams, L. Grace, Mark D. Starr, William T. Barry, Andrew Berchuck, Susan K. Murphy, Angeles Alvarez Secord	2011	32
13	Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth Journal of Clinical Investigation ·Erik H. Knelson, Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen Marcus, Gerard C. Blobe	2014	30
14	Indirect effects and infants' reaction to strangers. Developmental Psychology ·Candice Feiring, Michael Lewis, Mark D. Starr	1984	29
15	Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer Cell Reports ·Zainab Shonibare, Mehri Monavarian, Kathleen O’Connell, Diego Altomare, Abigail Shelton, Shubham Mehta, Renata Jaskula‐Sztul, Rébécca Phaëton, Mark D. Starr, Regina S. Whitaker, Andrew Berchuck, Andrew B. Nixon, Rebecca C. Arend, Nam Y. Lee, C. Ryan Miller, Nadine Hempel, Karthikeyan Mythreye	2022	27
16	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer Gynecologic Oncology ·Angeles Alvarez Secord, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert C. Squatrito, Laura J. Havrilesky, Anne C. Gabel, Mark D. Starr, John C. Brady, Andrew B. Nixon, Linda Duska	2019	27
17	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma Clinical Genitourinary Cancer ·Rhonda L. Bitting, Patrick Healy, Patricia Creel, James Turnbull, Karla K. Morris, Sarah Yenser Wood, Herbert I. Hurwitz, Mark D. Starr, Andrew B. Nixon, Andrew J. Armstrong, Daniel J. George	2013	24
18	Modulation of circulating protein biomarkers following TRC105 (anti‐endoglin antibody) treatment in patients with advanced cancer Cancer Medicine ·Yingmiao Liu, Mark D. Starr, John C. Brady, Andrew Dellinger, Herbert Pang, Bonne J. Adams, Charles P. Theuer, Nam Y. Lee, Herbert I. Hurwitz, Andrew B. Nixon	2014	23
19	The Balance of Cell Surface and Soluble Type III TGF-β Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells Neoplasia ·Catherine E. Gatza, Jennifer Elderbroom, Sun Young Oh, Mark D. Starr, Andrew B. Nixon, Gerard C. Blobe	2014	22
20	A phase I study ofABT‐510 plus bevacizumab in advanced solid tumors Cancer Medicine ·Hope E. Uronis, Stephanie M. Cushman, Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, Mark D. Starr, Haiyan Li, Kellen L. Meadows, Jon P. Gockerman, Herbert Pang, Herbert I. Hurwitz	2013	21

About Mark D. Starr

Mark D. Starr is a scholar working on Oncology, Equine, Cancer Research, Hematology and Hepatology, having authored 49 papers that have together received 1.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (8 papers), TGF-β signaling in diseases (8 papers), Angiogenesis and VEGF in Cancer (8 papers), Cancer, Hypoxia, and Metabolism (5 papers), Lung Cancer Treatments and Mutations (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Genetic factors in colorectal cancer (4 papers) and Cancer Cells and Metastasis (4 papers). The work is most often cited by research in Immunology (606 citations), Cell Biology (419 citations), Immunology and Allergy (144 citations), Oncology (571 citations) and Hematology (212 citations). Mark D. Starr has collaborated with scholars based in United States, Hong Kong and Canada. Frequent co-authors include Andrew B. Nixon, Mervin C. Yöder, Susan Mineka, S.A. Johnson, Xiaodong Xie, Michael J. Ferkowicz, Weiming Li, W. Christopher Shelley, Paul R. Morrison and Herbert I. Hurwitz. Their work appears in journals such as Journal of Clinical Oncology, Cancer Medicine, Journal of Clinical Investigation, Molecular Cancer Therapeutics and Developmental Psychology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact